CN117837765A - Probiotic composition with stomach nourishing and claustrophobic resisting functions and stomach nourishing and claustrophobic resisting nutrient - Google Patents
Probiotic composition with stomach nourishing and claustrophobic resisting functions and stomach nourishing and claustrophobic resisting nutrient Download PDFInfo
- Publication number
- CN117837765A CN117837765A CN202410049408.1A CN202410049408A CN117837765A CN 117837765 A CN117837765 A CN 117837765A CN 202410049408 A CN202410049408 A CN 202410049408A CN 117837765 A CN117837765 A CN 117837765A
- Authority
- CN
- China
- Prior art keywords
- stomach
- claustrophobic
- nourishing
- parts
- resisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 210000002784 stomach Anatomy 0.000 title claims abstract description 50
- 239000006041 probiotic Substances 0.000 title claims abstract description 47
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 47
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 40
- 230000006870 function Effects 0.000 title claims abstract description 31
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 20
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 37
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 36
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 36
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 34
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 20
- 229940105922 elm extract Drugs 0.000 claims abstract description 19
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 16
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 13
- MORUQNQGRSLTCD-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;zinc Chemical compound [Zn].NCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 MORUQNQGRSLTCD-FJXQXJEOSA-N 0.000 claims abstract description 6
- 229940075000 frankincense extract Drugs 0.000 claims abstract description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 14
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 14
- 239000011701 zinc Substances 0.000 claims description 14
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- 108010087806 Carnosine Proteins 0.000 claims description 12
- 241000717739 Boswellia sacra Species 0.000 claims description 10
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 10
- 239000004863 Frankincense Substances 0.000 claims description 10
- 229940044199 carnosine Drugs 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229940093476 ethylene glycol Drugs 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 3
- 239000007951 isotonicity adjuster Substances 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000000052 comparative effect Effects 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 210000001156 gastric mucosa Anatomy 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 9
- 208000007882 Gastritis Diseases 0.000 description 8
- 230000002633 protecting effect Effects 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 108700035912 polaprezinc Proteins 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001608538 Boswellia Species 0.000 description 2
- 235000018062 Boswellia Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- GFWBKUDRXMQSFD-FJXQXJEOSA-M 3-aminopropanoyl-[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]azanide;zinc Chemical compound [Zn].NCCC(=O)[N-][C@H](C(O)=O)CC1=CN=CN1 GFWBKUDRXMQSFD-FJXQXJEOSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a probiotic composition with stomach nourishing and claustrophobic resisting functions, a stomach nourishing and claustrophobic resisting nutrient and application of the probiotic composition with stomach nourishing and claustrophobic resisting functions in preparing products for resisting helicobacter pylori and preventing gastric ulcer. The probiotic composition with the stomach nourishing and claustrophobic resisting functions comprises the following components in parts by weight: 20-40 parts of elm extract, 20-40 parts of lactobacillus reuteri complex, 10-20 parts of L-glutamine, 2-6 parts of frankincense extract and 1-3 parts of L-carnosine zinc. Wherein the lactobacillus reuteri complex comprises lactobacillus reuteri strain No. DSM 17648. The probiotic composition and the stomach-nourishing and anti-claustria nutrient provided by the invention have the synergistic effect, and the effects of preventing and treating gastric ulcer and further improving the stomach-protecting effect are realized by effectively eliminating helicobacter pylori.
Description
Technical Field
The invention relates to the technical field of nutrition and health care, in particular to a probiotic composition with stomach nourishing and claustrophobic resisting functions, a stomach nourishing and claustrophobic resisting nutrient and application thereof in preparing products for resisting helicobacter pylori and preventing gastric ulcer.
Background
Helicobacter pylori (Helicobacter pylori, hp) is gram-negative obligate tenxybacteria planted in human stomach, is a main causative agent of stomach diseases such as chronic gastritis and peptic ulcer, and is the most definite and controllable risk factor of stomach cancer. Helicobacter pylori was defined by the world health organization as a type i carcinogen in 1994, and since then, a number of guidelines and expert consensus in both international and domestic states emphasized that eradication of helicobacter pylori was effective in preventing the occurrence of gastric cancer. As an important human pathogen, about half of the population worldwide infects helicobacter pylori.
At present, the scheme of eradicating helicobacter pylori is changed from triple to quadruple, the course of treatment is continuously prolonged, the types and the doses of antibiotics are continuously adjusted, the curative effect is limited, but the side effect is gradually increased, and more patients fail to repeatedly treat. The causes of failure to eradicate helicobacter pylori include treatment irregularities, poor patient compliance, resistance of helicobacter pylori to antibiotics, etc., where resistance is one of the most significant causes of decline in eradication rate of helicobacter pylori has become one of the greatest challenges of treatment.
In recent years, the use of probiotics has become one of the important means for supporting intestinal health and immunity, and a large number of in vitro researches, animal experiments and clinical observations show that the probiotics have the advantages of reducing adverse reactions and improving eradication rate in the aspect of assisting helicobacter pylori resistance, and are beneficial supplements of conventional therapies.
However, the probiotics for assisting in resisting helicobacter pylori are numerous in species, various in combination and different in dosage and time, and most of the stomach nourishing probiotics on the market are unilateral products, and have no effects of comprehensively nourishing and protecting stomach and resisting claustria. The effect of the active probiotics on resisting claustria is not clinically verified, and meanwhile, the effect of omnibearing stomach nourishing and protecting is not achieved, but the existing lactobacillus reuteri single probiotics only have the effect of resisting claustria, have the effects of protecting gastric mucosa, relieving stomachache, resisting bacteria, resisting inflammation and the like, and cannot meet the stomach nourishing requirements of people on resisting helicobacter pylori, preventing gastric ulcer and the like.
Accordingly, improvements are needed in the art.
Disclosure of Invention
In the prior art, the existing Lactobacillus reuteri single probiotics only have the anti-claustrial effect, have no effects of protecting gastric mucosa, relieving stomachache, resisting bacteria, resisting inflammation and the like, and cannot meet the requirements of people on gastric nourishment such as anti-helicobacter pylori and gastric ulcer prevention, so the invention provides a probiotic composition with the functions of nourishing stomach, resisting claustrial nutrition and application of the probiotic composition with the functions of nourishing stomach to preparation of products for resisting helicobacter pylori, preventing stomach discomfort such as gastric ulcer and the like.
To achieve the above object, in a first aspect, the present invention provides a probiotic composition having stomach nourishing and anti-claustrophobic functions, comprising the following components: elm extract, lactobacillus reuteri complex comprising lactobacillus reuteri strain number DSM17648, L-glutamine, olibanum extract and L-zinc carnosine, wherein the L-zinc carnosine is beta-alanyl-L-zinc histidine.
In one implementation, the composition comprises the following components in parts by weight: 20-40 parts of elm extract, 20-40 parts of lactobacillus reuteri complex, 10-20 parts of L-glutamine, 2-6 parts of frankincense extract and 1-3 parts of L-zinc carnosine.
In one implementation, the lactobacillus reuteri complex is a Pylopass lactobacillus reuteri.
In a second aspect, the present invention provides a stomach-nourishing anti-claustrophobic nutrient comprising a probiotic composition as described above having stomach-nourishing anti-claustrophobic function.
In one implementation, the stomach-nourishing anti-claustrophobic nutrient further comprises: a nutritionally acceptable carrier or adjuvant.
In one implementation, the nutritionally acceptable carrier or adjuvant comprises any one or combination of stabilizers, wetting agents, emulsifiers, binders, and isotonic agents.
In one implementation, the nutritionally acceptable carrier or adjuvant comprises any one or combination of gelatin, albumin, water, physiological saline, glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, and amino acids.
In one implementation, the stomach-nourishing anti-claustrophobic nutrient is any one of a tablet, a granule, a powder, a capsule, a solution, a suspension, an emulsion and a freeze-dried preparation.
In a third aspect, the invention also provides the use of a probiotic composition with stomach nourishing and anti-claustrial functions for the preparation of a product for the anti-helicobacter pylori and the prevention of gastric ulcers.
The beneficial effects are that: the probiotic composition and the stomach-nourishing anti-claustrophobic nutrient provided by the invention have the advantages that the added lactobacillus reuteri minus compound reduces the number of helicobacter pylori in the stomach, so that the helicobacter pylori load of healthy adult infection is obviously reduced, and the risk of gastritis and gastric ulcer is reduced; simultaneously adding zinc carnosine and glutamine for repairing gastric mucosa and preventing gastric ulcer; the elm extract can promote repair of gastric mucosa by promoting angiogenesis; by adding natural plant extracts such as Boswellia indicum and elm extract, the effects of relieving gastritis, stomach ache and acid regurgitation and heartburn are achieved; the added components have a synergistic effect, and the helicobacter pylori is effectively removed to prevent and treat gastric ulcer, so that the stomach protecting effect is improved; the probiotic composition with stomach nourishing and claustrophobic resisting functions is non-drug treatment, and is safe and free of side effects.
Detailed Description
The present invention will be described in further detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention. Furthermore, the descriptions of the terms "one embodiment," "some embodiments," "examples," "particular examples," or "some examples," etc., described below mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, schematic representations of the above terms are not necessarily for the same embodiment or example. The technical features of the respective embodiments of the present invention may be combined with each other as long as they do not collide with each other.
The invention provides a probiotic composition with stomach nourishing and claustrophobic resisting functions, which comprises the following components: elm extract, lactobacillus reuteri complex, L-glutamine, olibanum extract and L-carnosine zinc, said L-carnosine zinc being beta-alanyl-L-histidine zinc. Preferably, the probiotic composition with stomach nourishing and claustrophobic resisting functions comprises the following components in parts by weight: 20-40 parts of elm extract, 20-40 parts of lactobacillus reuteri complex, 10-20 parts of L-glutamine, 2-6 parts of frankincense extract and 1-3 parts of L-zinc carnosine. Further, the lactobacillus reuteri complex comprises lactobacillus reuteri with strain number of DSM17648 and strain number of 1000 hundred million CFU/g.
Specifically, the lactobacillus reuteri compound is selected as Pyloplass lactobacillus reuteri. The Pylopasts lactobacillus is obtained by fermentation of lactobacillus reuteri DSM17648 probiotic strain, and is composed of inactivated cells, and is therefore stable at room temperature. It can reduce helicobacter pylori load in stomach by a unique mode of action, thereby reducing the risk of developing gastritis and gastric ulcer. Pyloplass lactobacillus reuteri was identified as selectively binding to helicobacter pylori cells under in vivo gastric conditions. Specifically, the Pylopastase lactobacillus is physically removed, and the surface protein structure of helicobacter pylori is identified and combined with the physical removal, so that a copolymer is formed. The copolymer is expelled from the body through the gastrointestinal tract, thereby reducing the number of helicobacter pylori in the stomach. In addition, the lactobacillus reuteri complex is only aimed at type I and type II helicobacter pylori, is not aimed at other symbiotic bacteria, and does not influence other beneficial bacteria in human bodies.
Specifically, the elm extract contains abundant flavonoid components, and the flavonoid components can inhibit the release of stomach inflammation-related cytokines, reduce stomach tissue inflammatory response and have obvious anti-inflammatory effect. Meanwhile, the active ingredients of the elm extract have strong biological activity, can promote the repair of gastric mucosa, accelerate the repair of gastric mucosa and shorten the healing time by promoting the angiogenesis, stimulating the synthesis of collagen and other mechanisms.
In particular, glutamine is a non-essential amino acid that reduces oxidative damage in stomach tissue, prevents peptic ulcers, and improves healing of ulcers in the stomach.
Specifically, the olibanum extract can increase the thickness of regenerated gastric mucosa, reduce the number of saccular distending glands, increase the content of mucoperiodic acid leucofuchsin, increase the content of granulomatous tissue collagen and reduce the number of inflammatory cell infiltration. It has effects in reducing free acidity in stomach, resisting helicobacter pylori and relieving inflammation. Meanwhile, the olibanum extract is also effective on helicobacter pylori infection in vitro.
Specifically, zinc carnosine is a chelate of zinc and L-carnosine, and is fully called: beta-alanyl-L-Zinc histidine (Beta-alanyl-L-Histidinato Zinc), which contains 23% Zinc and 77% L-carnosine, is a gastric mucosa protectant, and can be clinically used for treating gastric ulcers. In the probiotic composition with the stomach nourishing and claustrophobic resisting functions, the zinc carnosine provides nutrition support for healing of gastrointestinal mucosa, can promote secretion of healthy gastric mucus, exerts antioxidant property, and can inhibit expression of cytokines, so that the probiotic composition is beneficial to protecting the gastric mucosa and can promote digestion of the gastrointestinal tract.
Example 1
The probiotic composition with stomach nourishing and claustrophobic resisting functions in the embodiment 1 comprises the following components in parts by weight: 30 parts of elm extract, 40 parts of lactobacillus reuteri complex, 15 parts of L-glutamine, 4 parts of frankincense extract and 2 parts of L-zinc carnosine, wherein the lactobacillus reuteri contains lactobacillus reuteri with the strain number of DSM17648 and the strain number of 1000 hundred million CFU/g. Wherein the lactobacillus reuteri compound adopts the Pyloplass cube which is purchased in the market.
Example 2
The probiotic composition with stomach nourishing and claustrophobic resisting functions in the embodiment 1 comprises the following components in parts by weight: 30 parts of elm extract, 30 parts of lactobacillus reuteri complex, 10 parts of L-glutamine, 4 parts of olibanum extract and 1 part of L-zinc carnosine.
Example 3
The probiotic composition with stomach nourishing and claustrophobic resisting functions in the embodiment 1 comprises the following components in parts by weight: 40 parts of elm extract, 20 parts of lactobacillus reuteri complex, 20 parts of L-glutamine, 4 parts of olibanum extract and 3 parts of L-zinc carnosine.
Example 4
The probiotic composition with stomach nourishing and claustrophobic resisting functions in the embodiment 1 comprises the following components in parts by weight: 20 parts of elm extract, 30 parts of lactobacillus reuteri complex, 15 parts of L-glutamine, 2 parts of olibanum extract and 3 parts of L-zinc carnosine.
Example 5
The probiotic composition with stomach nourishing and claustrophobic resisting functions in the embodiment 1 comprises the following components in parts by weight: 30 parts of elm extract, 30 parts of lactobacillus reuteri complex, 10 parts of L-glutamine, 6 parts of olibanum extract and 1 part of L-zinc carnosine.
Comparative example 1
The comparative example is different from the composition of the probiotic composition having stomach nourishing and anti-claustria function in example 1 in that only elm extract is not contained.
Comparative example 2
The comparative example is distinguished from the composition of the probiotic composition having stomach nourishing and anti-claustria function in example 1 in that only lactobacillus reuteri complex is not contained.
Comparative example 3
The comparative example is different from the composition of the probiotic composition having the stomach nourishing and anti-claustrophobic functions of example 1 in that only L-glutamine is not contained.
Comparative example 4
The comparative example is different from the composition of the probiotic composition having stomach nourishing and anti-claustrophobic functions of example 1 in that only the olibanum extract is not contained.
Comparative example 5
The comparative example is distinguished from the composition of the probiotic composition having stomach nourishing and anti-claustrophobic functions of example 1 in that it contains no L-carnosine zinc only.
Experiment 1: anti-helicobacter pylori assay
The specific experimental process comprises the following steps:
(1) Culturing helicobacter pylori bacterial liquid: culturing helicobacter pylori to logarithmic phase, collecting 5mL bacterial liquid, centrifuging at 5000g for 5min, re-suspending bacterial cells with TSB culture medium, and adjusting bacterial liquid concentration to 1×10 6 CFU/mL。
(2) Addition of a probiotic composition: under aseptic conditions, 5mg of the probiotic compositions in each example and comparative example are respectively taken and dissolved in aseptic water, and stirred and dissolved; a96-well plate was prepared, 100. Mu.L of the bacterial liquid of the above step (1) and 95. Mu.L of the medium were added to each well, and 5. Mu.L of the compositions prepared in examples 1 to 5 and comparative examples 1 to 5 were added, respectively, and a blank control was 5. Mu.L of the solution of LDMSO, and 3 replicates were set for each treatment. The 96-well plate was incubated at 37℃with shaking at 150rpm for 48h.
(3) Measuring the growth inhibition effect: whether the probiotic composition has an effect of inhibiting helicobacter pylori is verified by measuring the number of colonies in the culture.
Wherein, the bacterial liquid concentration is reflected by a value of 0D600, and the calculation formula of the bacteriostasis rate (%) is as follows:
(0D 600 control bacterial solution-0D 600 treated bacterial solution)/0D 600 control bacterial solution x100%
The experimental results are shown in table 1:
table 1:
the experimental results in Table 1 show that the compositions of examples and comparative examples significantly inhibit helicobacter pylori, wherein the effect of the examples is better than that of either component alone and significantly better than that of the comparative examples. The composition components of the invention are shown to have a better synergistic effect in reducing helicobacter pylori load in healthy adults, thereby reducing the risk of developing gastritis and gastric ulcers.
Experiment 2: experiment for treating gastric ulcer
Experimental materials: the compositions prepared in examples 1-5 and comparative examples 1-5 were dissected with a ruler, microinjectors, glacial acetic acid, laboratory animals (SD healthy rats).
Dose selection: according to the formulas of examples 1-5 and comparative examples 1-5, purified water was added for dilution and dissolution, and after thorough mixing, a solution of 20mg/mL was prepared, stored in a refrigerator at 4℃and administered at a dose of 200mg/kg of rat body weight.
The experimental method comprises the following steps: method for impregnating chronic gastric ulcer model by using glacial acetic acid
The SD rats were randomly divided into 13 groups of 8, each of which was a normal control group (physiological saline instead of glacial acetic acid), a model control group (physiological saline 5 mL/kg), an inactivated Lactobacillus reuteri group (inactivated Lactobacillus reuteri 200 mg/kg), and formulation groups of examples 1 to 5 and comparative examples 1 to 5 (dosages of 200 mg/kg), respectively.
Animals which are fasted and not fasted for 24 hours are anesthetized by diethyl ether, each mouse is subjected to laparotomy, a glass tube with the inner diameter of 5mm and the length of 30mm is vertically placed on the mucous membrane surface of the stomach body, glacial acetic acid is added into the lumen, and after 1.5 minutes, the glacial acetic acid is dipped by a cotton swab, an operation incision is sutured, and normal diet and water after operation are performed. The following day was started, and after 14 days of continuous administration of the test sample, the stomach was dissected and fixed with formaldehyde, and the area of gastric ulcer was measured, and the average value of the area of ulcer was used as an ulcer evaluation index, and the results are shown in table 2.
Table 2:
the experimental results in table 2 show that the compositions in examples and comparative examples can significantly reduce gastric mucosal injury caused by glacial acetic acid impregnation, inhibit ulcer formation, and promote gastric mucosal recovery. The effect of the examples is better than that of either component alone and is significantly better than that of the comparative examples. The composition components of the invention have better synergistic effect in inhibiting ulcer formation and promoting gastric mucosa recovery.
The invention also provides a stomach-nourishing and claustrophobic-resisting nutrient which comprises the probiotic composition with the stomach-nourishing and claustrophobic-resisting functions. The stomach nourishing and claustrophobic resisting nutrient further comprises: a nutritionally acceptable carrier or adjuvant. Specifically, the carrier or auxiliary materials acceptable in nutrition comprise any one or combination of stabilizing agents, wetting agents, emulsifying agents, binders and isotonic agents. Preferably, the nutritionally acceptable carrier or adjuvant comprises any one or combination of gelatin, albumin, water, physiological saline, glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol and amino acids. Further, the stomach-nourishing anti-claustrophobic nutrient is any one of tablets, granules, powder, capsules, solutions, suspensions, emulsions and freeze-dried preparations. Preferably, the stomach-nourishing anti-claustrophobic nutrient is a capsule.
In summary, the probiotic composition and the nutrient for nourishing and resisting the claustria provided by the invention can obviously reduce the helicobacter pylori load of healthy adults by reducing the number of helicobacter pylori in the stomach through the added lactobacillus reuteri compound, thereby reducing the risk of gastritis and gastric ulcer; simultaneously adding zinc carnosine and glutamine for repairing gastric mucosa and preventing gastric ulcer; the elm extract can promote repair of gastric mucosa by promoting angiogenesis; by adding natural plant extracts such as Boswellia indicum and elm extract, the effects of relieving gastritis, stomach ache and acid regurgitation and heartburn are achieved; the added components have a synergistic effect, and the helicobacter pylori is effectively removed to prevent and treat gastric ulcer, so that the stomach protecting effect is improved; the probiotic composition with stomach nourishing and claustrophobic resisting functions is non-drug treatment, and is safe and free of side effects.
The foregoing description is only of the preferred embodiments of the present invention and is not intended to limit the scope of the invention, and all equivalent structures or equivalent processes using the teachings of this invention or directly or indirectly applied to other related technical fields are included in the scope of this invention.
Claims (9)
1. A probiotic composition with stomach nourishing and claustrophobic resisting functions, which is characterized by comprising the following components: elm extract, lactobacillus reuteri complex comprising lactobacillus reuteri with strain number DSM17648, L-glutamine, olibanum extract and L-carnosine zinc, wherein the L-carnosine zinc is beta-alanyl-L-histidine zinc.
2. The probiotic composition with stomach nourishing and claustrophobic resisting functions according to claim 1, which is characterized by comprising the following components in parts by weight: 20-40 parts of elm extract, 20-40 parts of lactobacillus reuteri complex, 10-20 parts of L-glutamine, 2-6 parts of frankincense extract and 1-3 parts of L-zinc carnosine.
3. The stomach-nourishing and claustrophobic-resisting probiotic composition according to claims 1 and 2, wherein the lactobacillus reuteri complex is lactobacillus payopass.
4. A stomach-nourishing and anti-claustrophobic nutrient, characterized by comprising the probiotic composition with stomach-nourishing and anti-claustrophobic functions as claimed in any one of claims 1 to 3.
5. The stomach-nourishing anti-claustrophobic nutrient of claim 4, further comprising: a nutritionally acceptable carrier or adjuvant.
6. The stomach-nourishing anti-claustrophobic nutrient of claim 5, wherein the nutritionally acceptable carrier or adjuvant comprises any one or a combination selected from the group consisting of stabilizers, wetting agents, emulsifiers, binders, and isotonic agents.
7. The stomach-nourishing anti-claustrophobic nutrient of claim 6, wherein the nutritionally acceptable carrier or adjuvant comprises any one or a combination of gelatin, albumin, water, physiological saline, glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, and amino acids.
8. The stomach-nourishing anti-claustrophobic nutrient of claim 4, wherein the stomach-nourishing anti-claustrophobic nutrient is in any one of a tablet, a granule, a powder, a capsule, a solution, a suspension, an emulsion, and a lyophilized preparation.
9. The application of a probiotic composition with stomach nourishing and anti-claustria functions in preparing products for resisting helicobacter pylori and preventing gastric ulcer is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410049408.1A CN117837765A (en) | 2024-01-12 | 2024-01-12 | Probiotic composition with stomach nourishing and claustrophobic resisting functions and stomach nourishing and claustrophobic resisting nutrient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410049408.1A CN117837765A (en) | 2024-01-12 | 2024-01-12 | Probiotic composition with stomach nourishing and claustrophobic resisting functions and stomach nourishing and claustrophobic resisting nutrient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117837765A true CN117837765A (en) | 2024-04-09 |
Family
ID=90530010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410049408.1A Pending CN117837765A (en) | 2024-01-12 | 2024-01-12 | Probiotic composition with stomach nourishing and claustrophobic resisting functions and stomach nourishing and claustrophobic resisting nutrient |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117837765A (en) |
-
2024
- 2024-01-12 CN CN202410049408.1A patent/CN117837765A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
| AU2006241320B2 (en) | A bacterial culture having effects of suppressing dermatitis development and accelarating skin wound healing, and product using the same | |
| US11623010B2 (en) | Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment | |
| CN114796283B (en) | Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition | |
| EP0363491B1 (en) | Bacterial preparation for prophylaxis and treatment of inflammatory processes and allergic diseases | |
| JPH09278662A (en) | Antiallergic agent | |
| CN117837765A (en) | Probiotic composition with stomach nourishing and claustrophobic resisting functions and stomach nourishing and claustrophobic resisting nutrient | |
| EP1186295B1 (en) | Pharmaceutical preparations containing extracts of soy isoflavone and probiotic micro-organisms | |
| WO2021249402A1 (en) | Effects of cell-free fat liquid extract on macrophage polarization modulation and disease treatment | |
| JP2005289950A (en) | Lipase inhibitor comprising water extraction component of eucommia ulmoides leaf | |
| JP4633367B2 (en) | Anti-Helicobacter pylori | |
| CN114557447A (en) | Composite nutriment and preparation method thereof | |
| KR20230089336A (en) | Composition for preventing and treating vaginitis and urinary incontinence containing snake venom and PDRN. | |
| JP2855283B2 (en) | Anti-ulcer agent and method for producing the same | |
| CN113384662A (en) | Helicobacter pylori-resistant probiotic composition and preparation method and application thereof | |
| KR100509249B1 (en) | Drugs, foods, drinks and feeds containing cocoa component | |
| CN112656887B (en) | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof | |
| KR20030021298A (en) | The composition of immune enhancer and intestinal regulator for animal | |
| WO2022194094A1 (en) | Use of cell-free fat extract for treating spinal cord injury | |
| US20230103514A1 (en) | A topical composition comprising an extract of combined herbs comprising longanae arillus for the skin regeneration and the treatment or alleviation of skin wound and the use thereof | |
| WO2022100400A1 (en) | Use of cell-free fat extract for treatment of nonalcoholic steatohepatitis | |
| KR20220040689A (en) | Composition for ameliorating or treating scar and composition for preventing or treating atopic dermatitis comprising ginsenoside | |
| KR20010048289A (en) | Compositions for angiogenesis and preventing and treating arthritis comprising β-sitosterol | |
| WO1991011191A1 (en) | Pharmacological compositions containing extracts derived from gramineae plant family and uses thereof | |
| CN117617500A (en) | Functional formula powder suitable for postoperative recovery and preparation method and application method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |